The Creative Ways Drugmakers Are Delaying Generics
Drugmakers are increasingly embracing new tactics to protect billions of dollars in sales from generic competition. These strategies often involve patent trials, but that's not the only way companies are waylaying generic drugmakers.
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell explain why companies like AbbVie (NYSE: ABBV) are working so hard to delay generic competition, how legal battles can add years of sales to drugs facing patent expiration, and how reformulating existing drugs to last longer helps keep sales flowing at companies like Teva Pharmaceutical (NYSE: TEVA).
A full transcript follows the video.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€30.00
-0.990%
With 23 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 34 € there is a slightly positive potential of 13.33% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 30.0 €.
